Related Experiment Video
Updated: May 7, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Distinct host cell fates for human malignant melanoma targeted by oncolytic rodent parvoviruses
Ellen M Vollmers1, Peter Tattersall
1Medical Scientist Training Program, Yale University Medical School, 333 Cedar Street, New Haven, CT 06510, United States; Department of Genetics, Yale University Medical School, 333 Cedar Street, New Haven, CT 06510, United States.
Abstract:
The rodent parvoviruses are known to be oncoselective, and lytically infect many transformed human cells. Because current therapeutic regimens for metastatic melanoma have low response rates and have little effect on improving survival, this disease is a prime candidate for novel approaches to therapy, including oncolytic parvoviruses. Screening of low-passage, patient-derived melanoma cell lines for multiplicity-dependent killing by a panel of five rodent parvoviruses identified LuIII as the most melanoma-lytic. This property was mapped to the LuIII capsid gene, and an efficiently melanoma tropic chimeric virus shown to undergo three types of interaction with primary human melanoma cells: (1) complete lysis of cultures infected at very low multiplicities; (2) acute killing resulting from viral protein synthesis and DNA replication, without concomitant expansion of the infection, due to failure to export progeny virions efficiently; or (3) complete resistance that operates at an intracellular step following virion uptake, but preceding viral transcription.
Insights
Researchers identified LuIII, a rodent parvovirus, as a potent oncolytic agent against melanoma. This virus shows promise for novel melanoma therapies by selectively killing cancer cells.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Background:
- Metastatic melanoma has limited treatment options and poor survival rates.
- Oncolytic viruses, including rodent parvoviruses, are being explored as novel cancer therapies.
- Rodent parvoviruses exhibit oncoselectivity, effectively infecting transformed human cells.
Purpose of the Study:
- To identify and characterize novel oncolytic parvoviruses for metastatic melanoma treatment.
- To evaluate the efficacy of rodent parvoviruses against patient-derived melanoma cell lines.
Main Methods:
- Screening of five rodent parvoviruses against low-passage, patient-derived melanoma cell lines.
- Identification of LuIII as the most melanoma-lytic parvovirus.
- Mapping the melanoma-lytic property to the LuIII capsid gene.
- Characterization of chimeric virus interactions with primary human melanoma cells.
Main Results:
- LuIII demonstrated significant multiplicity-dependent killing of melanoma cells.
- The melanoma-lytic property was attributed to the LuIII capsid gene.
- A chimeric virus exhibited three distinct interactions with melanoma cells: complete lysis, acute killing without infection spread, and resistance.
- Interactions were dependent on viral multiplicity and cellular response.
Conclusions:
- LuIII is a highly melanoma-lytic parvovirus with potential as an oncolytic therapeutic.
- The LuIII capsid plays a crucial role in its oncoselectivity and lytic activity.
- Understanding the virus-cell interactions is key to optimizing parvovirus-based melanoma therapies.
